Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells

Shogo Okazaki, Fumi Nakatani, Kazue Masuko, Kenji Tsuchihashi, Shiho Ueda, Takashi Masuko, Hideyuki Saya, Osamu Nagano

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The use of monoclonal antibodies (mAbs) for cancer therapy is one of the most important strategies for current cancer treatment. The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, which regulates cancer cell proliferation, survival, and migration, is a major molecular target for antibody-based therapy. ErbB4/HER4, which contains a ligand-binding extracellular region, is activated by several ligands, including neuregulins (NRGs), heparin-binding EGF-like growth factor, betacellulin and epiregulin. Although there are clinically approved antibodies for ErbB1 and ErbB2, there are no available therapeutic mAbs for ErbB4, and it is not known whether ErbB4 is a useful target for antibody-based cancer therapy. In this study, we developed an anti-ErbB4 mAb (clone P6-1) that suppresses NRG-dependent activation of ErbB4 and examined its effect on breast cancer cell proliferation in the extracellular matrix.

Original languageEnglish
Pages (from-to)239-244
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume470
Issue number1
DOIs
Publication statusPublished - 2016 Jan 29

Fingerprint

Neuregulin-1
Chemical activation
Monoclonal Antibodies
Cells
Cell proliferation
Antibodies
Neuregulins
Ligands
Neoplasms
Oncology
Cell Proliferation
Receptor Protein-Tyrosine Kinases
Epidermal Growth Factor Receptor
Therapeutics
Cell Movement
Extracellular Matrix
Cell Survival
Clone Cells
Breast Neoplasms

Keywords

  • Breast cancer
  • ErbB4
  • Neuregulin
  • Neutralizing antibody
  • Three-dimensional culture

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells. / Okazaki, Shogo; Nakatani, Fumi; Masuko, Kazue; Tsuchihashi, Kenji; Ueda, Shiho; Masuko, Takashi; Saya, Hideyuki; Nagano, Osamu.

In: Biochemical and Biophysical Research Communications, Vol. 470, No. 1, 29.01.2016, p. 239-244.

Research output: Contribution to journalArticle

Okazaki, Shogo ; Nakatani, Fumi ; Masuko, Kazue ; Tsuchihashi, Kenji ; Ueda, Shiho ; Masuko, Takashi ; Saya, Hideyuki ; Nagano, Osamu. / Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells. In: Biochemical and Biophysical Research Communications. 2016 ; Vol. 470, No. 1. pp. 239-244.
@article{b5974f7628854f6f9b3e488359520605,
title = "Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells",
abstract = "The use of monoclonal antibodies (mAbs) for cancer therapy is one of the most important strategies for current cancer treatment. The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, which regulates cancer cell proliferation, survival, and migration, is a major molecular target for antibody-based therapy. ErbB4/HER4, which contains a ligand-binding extracellular region, is activated by several ligands, including neuregulins (NRGs), heparin-binding EGF-like growth factor, betacellulin and epiregulin. Although there are clinically approved antibodies for ErbB1 and ErbB2, there are no available therapeutic mAbs for ErbB4, and it is not known whether ErbB4 is a useful target for antibody-based cancer therapy. In this study, we developed an anti-ErbB4 mAb (clone P6-1) that suppresses NRG-dependent activation of ErbB4 and examined its effect on breast cancer cell proliferation in the extracellular matrix.",
keywords = "Breast cancer, ErbB4, Neuregulin, Neutralizing antibody, Three-dimensional culture",
author = "Shogo Okazaki and Fumi Nakatani and Kazue Masuko and Kenji Tsuchihashi and Shiho Ueda and Takashi Masuko and Hideyuki Saya and Osamu Nagano",
year = "2016",
month = "1",
day = "29",
doi = "10.1016/j.bbrc.2016.01.045",
language = "English",
volume = "470",
pages = "239--244",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells

AU - Okazaki, Shogo

AU - Nakatani, Fumi

AU - Masuko, Kazue

AU - Tsuchihashi, Kenji

AU - Ueda, Shiho

AU - Masuko, Takashi

AU - Saya, Hideyuki

AU - Nagano, Osamu

PY - 2016/1/29

Y1 - 2016/1/29

N2 - The use of monoclonal antibodies (mAbs) for cancer therapy is one of the most important strategies for current cancer treatment. The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, which regulates cancer cell proliferation, survival, and migration, is a major molecular target for antibody-based therapy. ErbB4/HER4, which contains a ligand-binding extracellular region, is activated by several ligands, including neuregulins (NRGs), heparin-binding EGF-like growth factor, betacellulin and epiregulin. Although there are clinically approved antibodies for ErbB1 and ErbB2, there are no available therapeutic mAbs for ErbB4, and it is not known whether ErbB4 is a useful target for antibody-based cancer therapy. In this study, we developed an anti-ErbB4 mAb (clone P6-1) that suppresses NRG-dependent activation of ErbB4 and examined its effect on breast cancer cell proliferation in the extracellular matrix.

AB - The use of monoclonal antibodies (mAbs) for cancer therapy is one of the most important strategies for current cancer treatment. The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, which regulates cancer cell proliferation, survival, and migration, is a major molecular target for antibody-based therapy. ErbB4/HER4, which contains a ligand-binding extracellular region, is activated by several ligands, including neuregulins (NRGs), heparin-binding EGF-like growth factor, betacellulin and epiregulin. Although there are clinically approved antibodies for ErbB1 and ErbB2, there are no available therapeutic mAbs for ErbB4, and it is not known whether ErbB4 is a useful target for antibody-based cancer therapy. In this study, we developed an anti-ErbB4 mAb (clone P6-1) that suppresses NRG-dependent activation of ErbB4 and examined its effect on breast cancer cell proliferation in the extracellular matrix.

KW - Breast cancer

KW - ErbB4

KW - Neuregulin

KW - Neutralizing antibody

KW - Three-dimensional culture

UR - http://www.scopus.com/inward/record.url?scp=84956591552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956591552&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2016.01.045

DO - 10.1016/j.bbrc.2016.01.045

M3 - Article

C2 - 26780728

AN - SCOPUS:84956591552

VL - 470

SP - 239

EP - 244

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -